Periperal Antinociception by Carbamazepine in an Inflammatory Mechanical Hyperalgesia Model in the Rat: a New Target for Carbamazepine?

Sonja Vučković1,*, Maja Tomić2, Radica Stepanović-Petrović2, Nenad Ugrešić2, Milica Prostran1, and Bogdan Bošković3

1Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Dr Subotića 1, P.O. Box 840, 11129 Belgrade, Serbia and Montenegro
2Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, P.O. Box 146, Vojvode Stepe 450, 11221 Belgrade, Serbia and Montenegro
3Medical Military Academy, Crnotravska 17, 11000 Belgrade, Serbia and Montenegro

Received November 7, 2005; Accepted January 31, 2006

Abstract. This study investigated whether carbamazepine could produce local peripheral antinociception in a rat model of inflammatory mechanical hyperalgesia, and whether adenosine receptors are involved. Carbamazepine (100–1000 nmol/paw) coadministered with a pro-inflammatory compound, concanavalin A, into the hind paw caused a significant dose- and time-dependent anti-hyperalgesia. Co-administration of caffeine (250–1000 nmol/paw), a non-selective adenosine-receptor antagonist, as well as DPCPX (10–30 nmol/paw), a selective adenosine A1-receptor antagonist, with carbamazepine, significantly depressed its anti-hyperalgesic effect. Drugs injected into the contralateral hind paw did not produce significant effects. These results suggest that carbamazepine produces local peripheral anti-hyperalgesia via peripheral adenosine A1 receptors.

Keywords: local carbamazepine, inflammatory mechanical hyperalgesia, adenosine A1 receptor

Carbamazepine is a well known anticonvulsant drug that has been widely used as an analgesic in the treatment of neuropathic pain. In recent years, increasing evidence appeared that carbamazepine is effective in different animal models of pain, but the sites and mechanisms of its action are not completely understood (1–5).

In our previous study, we have demonstrated that systemic carbamazepine reversed the hyperalgesia induced by intraplantar administration of a pro-inflammatory compound, concanavalin A (Con A), into the rat hind paw and that this effect is mediated via adenosine A1 receptors (4). As it is well known that activation of both central and peripheral adenosine A1 receptors inhibits pain in rodents (6), this finding raised further questions related to the potential involvement of the peripheral adenosine receptors in the carbamazepine-induced antinociception. The interaction of carbamazepine with central adenosine receptors has already been demonstrated in receptor binding studies (1, 7), as well as in a behavioral study of nociception (8). On the other hand, the interaction of carbamazepine with adenosine receptors in peripheral pain pathways has not been evaluated before.

The present study had two objectives. First, to determine the effect of locally administered carbamazepine on inflammatory mechanical hyperalgesia in the hind paw of the rat. Second, to determine a potential involvement of adenosine receptors in the local peripheral action of carbamazepine by assessing the effect of caffeine (a nonselective adenosine A1 and A2 receptor antagonist) and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) (a selective adenosine A1-receptor antagonist) on carbamazepine-induced antinociception.

Groups of 6–8 male Wistar rats (180–220 g) were used. The investigation conforms with the Guide for the
Peripheral Carbamazepine Antinociception

Induction of inflammation and the paw pressure test was performed as previously described (4). Briefly, the rat was placed with its hind paws on two transducer platforms of the apparatus (Hugo Sachs Elektronik, March-Hugstetten, Germany) and pushed slowly and smoothly downwards, until one of the paws exceeds the trigger level set at 100 g. The difference (d) in pressures (in grams) applied to non-inflamed (vehicle-injected) and inflamed (Con A-injected) rat hind paws is determined after each measurement. Firstly, in order to examine the peripheral effect of carbamazepine, the drug and the Con A were coadministered intraplantarly (i.pl.), into the right hind paw (Fig. 1A). Control animals received the same volume of Con A (i.pl.) dissolved in the same vehicle (Fig. 1B). To exclude the possible systemic effect of intraplantarly injected caffeine or DPCPX, the highest tested dose of each antagonist was given contralaterally (Fig. 1E). Finally, the effects of coadministration of the highest doses of each antagonist were evaluated and compared with the effect of Con A alone (Fig. 1B). Carbamazepine (Sigma-Aldrich Chemie GmbH, Munich, Germany), caffeine (Galeni ka, Belgrade, Serbia and Montenegro), and DPCPX (Sigma-Aldrich Chemie GmbH) were dissolved or suspended in a vehicle containing 50% polyethylene glycol 400 (PEG 400) and 50% saline and sonicated for 15 min for proper distribution. Con A was used in a fixed dose of 0.8 mg/paw. All substances were injected intraplantarly in a final volume of 0.1 ml/paw. Results are expressed as means ± S.E.M. Calculations for percent antihyperalgesic activity (%AA), percent inhibition of antihyperalgesic activity (%I), and ED_{50} value were done according to references 4, 9, and 10. Statistical comparisons were made by Student’s t-test or analysis of variance (One-Way ANOVA), followed by Tukey’s HSD test (10). A P<0.05 was considered significant.

The coadministration of carbamazepine (100 – 1000 nmol/paw, i.pl.) with Con A produced a significant dose- and time-dependent reduction in differences in forces exerted by inflamed and non-inflamed rat hind paw in a paw pressure test (Fig. 2A). The least ED_{50} value (95% confidence limits) of 920 (512 – 1654) nmol/paw (0.217 mg/paw) was obtained 150 min after i.pl. injection. Coadministration of caffeine (250 and 1000 nmol/paw, i.pl.), as well as DPCPX (10 and 30 nmol/paw, i.pl.) with carbamazepine (600 nmol/paw) into the rat hind paw significantly decreased the antihyperalgesic effect of carbamazepine in a dose- and time-dependent manner (Fig. 2: B and C).

Peripheral coadministration of caffeine (1000 nmol/paw, i.pl.) or DPCPX (30 nmol/paw, i.pl.) with carbamazepine did not produce any antihyperalgesic effect (Fig. 2: D). The effects of carbamazepine, caffeine, and DPCPX were due to local effects, since they were not observed after administration of these drugs into the contralateral hind paw (Fig. 2: A, B, C). Peripheral coadministration of caffeine (1000 nmol/paw, i.pl.) or DPCPX (30 nmol/paw, i.pl.) with carbamazepine (600 nmol/paw) significantly decreased the antihyperalgesic effect of carbamazepine in a dose- and time-dependent manner (Fig. 2: B and C). The maximum inhibitory effects of 250 and 1000 nmol/paw of caffeine on carbamazepine-induced antinociception were 53.4%I and 79.4%I, respectively (not shown). The maximum inhibitory effects of 10 and 30 nmol/paw of DPCPX on carbamazepine-induced antinociception were 58.3%I and 85.2%I, respectively (not shown). The effects of carbamazepine, caffeine, and DPCPX were due to local effects, since they were not observed after administration of these drugs into the contralateral hind paw (Fig. 2: A, B, C). Peripheral coadministration of caffeine (1000 nmol/paw, i.pl.) or DPCPX (30 nmol/paw, i.pl.) with carbamazepine (600 nmol/paw) significantly decreased the antihyperalgesic effect of carbamazepine in a dose- and time-dependent manner (Fig. 2: B and C). The maximum inhibitory effects of 250 and 1000 nmol/paw of caffeine on carbamazepine-induced antinociception were 53.4%I and 79.4%I, respectively (not shown). The maximum inhibitory effects of 10 and 30 nmol/paw of DPCPX on carbamazepine-induced antinociception were 58.3%I and 85.2%I, respectively (not shown).

Care and Use of Laboratory Animals published by the U.S. National Institute of Health (NIH Publication No. 85 – 23, revised 1985).

Induction of inflammation and the paw pressure test was performed as previously described (4). Briefly, the rat was placed with its hind paws on two transducer platforms of the apparatus (Hugo Sachs Elektronik, March-Hugstetten, Germany) and pushed slowly and smoothly downwards, until one of the paws exceeds the trigger level set at 100 g. The difference (d) in pressures (in grams) applied to left and right hind paws. Predrug d was obtained 10 min before intraplantar injection. The right hind paw was injected immediately after the left one.
nmol/paw, i.pl.) with Con A failed to produce any significant effect on Con A-induced hyperalgesia ($P>0.05$, Student’s $t$-test, data not shown).

The present experiments revealed significant dose- and time-dependent local peripheral antinociceptive action of carbamazepine in an inflammatory mechanical hyperalgesia model in the rat. The local nature of this action was verified by the lack of effect of carbamazepine injected into the contralateral hind paw. In our previous study, we demonstrated that systemically administrated carbamazepine produces antinociception in the same model, but whether the drug acts centrally and/or peripherally remained undetermined (4). In the present study, the significant local effects of carbamazepine (100 – 1000 nmol/paw = 0.12 – 1.18 mg/kg, i.pl.) were attainable with much lower doses (up to 85 times lower) than the lowest effective systemic doses determined in our previous study (10 mg/kg, i.p.).
This could suggest that carbamazepine given systemically is able to achieve effective concentrations at the periphery and that there is considerable contribution of the peripheral antinociceptive effect to the net effect of systemically administered carbamazepine.

Earlier studies evaluated the antinociceptive potencies of carbamazepine administrated mostly by systemic and occasionally by a central route. Recently, some authors demonstrated that carbamazepine injected intraplantarly into the rat hind paw is a potent analgesic against acute thermal nociception in rats (11). The doses of carbamazepine they used were 3,000–6,000 times lower than the commonly used doses of lidocaine (1%–2% solution or 1–2 mg/0.1 ml), a well known and widely used local anesthetic. However, our study provides the first evidence on the local peripheral antihyperalgesic effect of carbamazepine in the experimental model of inflammatory pain. The potency of carbamazepine in our study is about 700 times lower than that reported by another group (11) (ED50 values: 0.21733 vs 0.00032 mg/paw, respectively). By comparison, doses of carbamazepine that produce a systemic antinociceptive effect vary among studies that use different animal models of nociception from about 0.3 to 300 mg/kg (2–5, 8).

It is well known that the purine nucleoside, adenosine, plays an important role in pain modulation. The adenosine A1 receptor is the predominant receptor subtype mediating antinociception both peripherally and centrally, while the A2A, A2B, and A3 receptors mediate nociception peripherally (6).

In the present experiments, the coadministration of nonselective adenosine A1- and A2-receptor antagonist, caffeine (250 and 1000 nmol/paw, i.pl.), with carbamazepine significantly depressed its local anti-hyperalgesic effect. As blockade of adenosine receptors is thought to underlie many of the pharmacological effects of caffeine (12), these observations suggest involvement of adenosine receptors in the anti-hyperalgesic effect of carbamazepine. However, the reversal of the anti-hyperalgesic effect of carbamazepine by a selective adenosine A1-receptor antagonist, DPCPX (10 and 30 nmol/paw, i.pl.), coadministered with carbamazepine revealed that carbamazepine exerts its effect most probably through activation of adenosine A1 receptors. In conclusion, the results of the present study indicate that carbamazepine produces local peripheral antinociception against inflammatory pain, and peripheral A1 receptors might be a new target for the analgesic effect of carbamazepine.

Acknowledgment

This work was supported by the Ministry of Science and Environmental Protection of Serbia.

References

6 Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery.